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 1 
Abstract 2 
Rapid detection of toxigenic Clostridium difficile strains is crucial for optimal management of 3 
patient with C. difficile infection (CDI). Currently, the « gold standards » for the diagnosis of 4 
CDI are the cytotoxicity assay and the toxigenic culture. However both methods are time 5 
consuming and results are not available before 24-48 hours. The objectives were to develop 6 
and evaluate a multiplex in-house real-time PCR for the simultaneous detection of toxigenic 7 
strains of C. difficile and the presumptive identification of the epidemic NAP1/027/BI strain 8 
from stools. Genomic DNA was extracted from stools using the NucliSENS miniMAG 9 
Platform (bioMérieux, La Balme-les-Grottes, France). Amplifications were performed using 10 
specific primers for tcdB and tcdC on ABI Prism 7300 (Applied Biosystem). Detection of 11 
amplicons was done using TaqMan probes. Analytical sensitivity of the multiplex real-time 12 
PCR for detecting tcdB was estimated to 10 UFC/g of stools. This assay was assessed from 13 
881 consecutive unformed stools from patients suspected of having CDI. The gold standard 14 
was the toxigenic culture for the diagnosis of CDI, and PCR ribotyping for the identification 15 
of the NAP1/027/BI strain. The prevalence of positive toxigenic culture was 9.31%. 16 
Compared to the toxigenic culture, the sensitivity, specificity, positive and negative predictive 17 
values were 86.59%, 97.43%, 78.02% and 98.57% for the real-time PCR and 70.73%, 100%, 18 
100% and 97.08% for the cytotoxicity assay. The epidemic clone NAP1/027/BI was neither 19 
detected by real-time PCR nor by the gold standard assay.  20 
These results indicated that our in-house real-time PCR assay was more rapid and sensitive 21 
than the cytotoxicity assay for the detection of toxigenic C. difficile from stool samples.  22 
 23 
 24 
 25 
26 
 3 
INTRODUCTION 1 
  2 
Clostridium difficile is currently responsible for 10 to 25% of cases of antibiotic-associated 3 
diarrhea and for virtually all cases of pseudomembranous colitis (PMC)(7, 20, 23). This spore 4 
forming bacterium has also emerged as the leading infectious cause of healthcare-associated 5 
diarrhea in adult patients. The epidemiology of C. difficile infections (CDI) has dramatically 6 
changed over the last decade (3, 13, 18, 39). Infections have been reported more frequent and 7 
more severe both in North America and Europe (6, 24, 28, 30). This trend is assumed to be 8 
due in part to the rapid emergence and spread of a specific hypervirulent clone of C. difficile 9 
belonging to PCR ribotype 027 (also characterized as toxinotype III, North America PFGE 10 
pulsotype 1 [NAP1] and restriction endonuclease analysis group BI). This clone has been 11 
shown to overproduce in vitro both toxins A and B. The overproduction was suggested to be 12 
related to the absence of functional TcdC, the negative regulator of toxin gene expression (27) 13 
by a single nucleotide deletion at position 117 in TcdC encoding gene (42). The NAP1/027/BI 14 
strain also produces a third toxin (binary toxin) and high quantity of spores, which 15 
disseminate easily in the hospital environment (2, 29). 16 
 17 
Prompt diagnosis of CDI is essential not only for patient management but also for swift 18 
implementation of control measures. Historically, the cytotoxicity assay has been considered 19 
as the « gold standard » for the diagnosis of C. difficile infections (11). However this method 20 
is time consuming, needs an incubation of at least 24h, and requires cell culture facilities. 21 
More recently, the toxigenic culture has been re-accepted as a gold standard (14, 15). But 22 
again, this technique is too long to be clinically useful. As of today, most laboratories have 23 
adopted enzyme immunoassays for toxins A and B in routine (5). These assays are easier to 24 
perform, more rapid and do not require specific technical skill. However they are not sensitive 25 
 4 
enough to be used as a stand-alone test for C. difficile diagnosis (14, 15, 17, 32). More 1 
recently, real-time PCR assays have been developed in order to overcome the lack of 2 
sensitivity of EIAs and to reduce the time of culture. These assays include in-house real-time 3 
PCR as well as Food and Drug Administration (FDA)-cleared commercial assays. Numerous 4 
clinical studies have shown that these assays exhibit the best concordance with the results of 5 
toxigenic culture as compared to enzyme immunoassays and could represent therefore a 6 
promising alternative for the diagnosis of CDI (17, 22, 25, 31, 35-38).  7 
The purpose of this study was to develop and to evaluate a multiplex real-time PCR for both 8 
the detection of toxigenic C. difficile strains from stools and the presumptive identification of 9 
NAP1/027/BI strain. 10 
(This work was presented at the 50th ICAAC meeting, Boston, 12 to 15 September 2010).  11 
 12 
 13 
MATERIALS AND METHODS 14 
 15 
Bacterial strains 16 
Bacterial strains were obtained from the national reference laboratory for C. difficile (Paris, 17 
France), from the Pasteur Institute (B. Dupuy, laboratoire Pathogénèse des bactéries 18 
anaérobies) and from Hines VA (S. Sambol, Hines, Illinois, USA). Sixty eight C. difficile 19 
strains were studied for the development of the real-time PCR including one non toxigenic 20 
strains (ATCC 43597), and 67 toxigenic strains from toxinotype 0 (n=10 including VPI 21 
10463), I (n=1), III (n=32 including CIP 107932), IV (n=4 including CIP 109239), V (n=4 22 
including CIP109238), VI (n=5), VII (n=1), VIII (n=3), IX (n=1), XII (n=3), XIV (n-=1), XX 23 
(n=1), XXIV (n=1). All strains from toxinotype III were characterized by PCR-ribotyping and 24 
tcdC sequencing. The analytical specificity of the assay was tested using 8 Clostridium spp. 25 
 5 
other than C. difficile: C. bifermentans (ATCC 638), C. amygdalinum (gift from MR Popoff, 1 
Institut Pasteur), C. innocuum (NCIB 10674), C. ramosum (ATCC 25582), C. sordellii (NCIB 2 
10717), C. perfringens (CIP 103409), C. tertium (ATCC 14573) and C. sphenoides (ATCC 3 
19403). DNA from strains was extracted with the Instagene Matrix kit (Bio-Rad, Ivry, 4 
France), as previously described (6). 5 
 6 
Study population and sample collection 7 
This prospective study was approved by the Comité de Protection des Personnes from Saint-8 
Antoine Hospital and by the Commission Nationale de l’Informatique et des Libertés (CNIL 9 
N° 1193577). Eligible patients included those with a suspected CDI for whom unformed 10 
stools specimens were submitted by physicians to the laboratory for C. difficile testing. 11 
Duplicate specimens (defined by stools samples from the same patient within a period of 10 12 
days) and specimens from patients under 18 years of age were excluded. 13 
Eight hundred and eighty one consecutive diarrheal stool samples (stools taking the shape of 14 
the container) were collected from May 2008 to February 2009 from patients hospitalized in 15 
four different university-affiliated hospitals in Paris (Tenon hospital, n=44; Saint-Antoine 16 
hospital, n=392 ; Pitié-Salpêtrière hospital, n=287) and surrounding (C. Foix/J. Rostang 17 
hospital, n=158). Stool samples were stored at +4°C until processing and analysis were done 18 
within 48 h of collection. Specimens were homogenized and then split: a portion of the 19 
specimen was used to test for PCR, culture and cytotoxicity assay. The remaining unformed 20 
stool was frozen at -80°C for subsequent controls. 21 
Additionally, five frozen stools from patients having a documented CDI due to 027 strain 22 
were also investigated  (obtained from J.P. Canonne,  Hôpital de Lens, France).  23 
 24 
Stool processing for real-time PCR 25 
 6 
DNA extraction was performed using the NucliSENS miniMAG Platform (bioMérieux, La 1 
Balme-les-Grottes, France) according to the manufacturer’s instructions. Stools were diluted 2 
1:20 in sterile PBS and homogenized. Two hundred microliters of this dilution were mixed 3 
with 2 ml of Nuclisens Lysis Buffer and 5 l of rv3865-containing plasmid (0,03 ng/µl). The 4 
nucleic acid extraction method was based on high-affinity magnetic silica particles. Briefly, 5 
under high salt conditions, nucleic acid binds to the silica particles. These silica particles act 6 
as a solid phase and non-nucleic acid components are removed by several washing steps 7 
performed in the NucliSens miniMAG disposable plastic tray. Finally, nucleic acids are eluted 8 
from the solid phase and the eluate is stored at +4°C until use. 9 
 10 
Real-time PCR 11 
Amplifications were performed either from purified genomic DNA or from crude DNA 12 
extracted from feces samples. A multiplex real-time PCR was developed for the simultaneous 13 
detection of the tcdB gene, the deletion at position 117 of tcdC gene and a DNA internal 14 
control. The internal control consisted of a plasmid containing part of the gene rv3865 from 15 
Mycobacterium tuberculosis (19). The internal control was added on initial processing of 16 
DNA extraction of stool samples. It acts as control of the general process (including DNA 17 
extraction step) and monitors the presence of PCR inhibitors. Primers and probes used in the 18 
assay are described in table 1. Primers and probes for tcdB were designed from the non repeat 19 
region of the known tcdB sequence (accession number n° NC_009089) using the Primer 3 20 
software (http://frodo.wi.mit.edu/primer3/). 21 
Amplification was performed in a 96-well PCR plate in the ABI Prism 7300 real-time PCR 22 
instrument (Applied Biosystems, Roche). A final volume of 20 µl was used containing 2 µl of 23 
extracted DNA, 10µl of TaqMan Master Mix (Roche, Minneapolis), 2 µl Mix containing 24 
Primers (200 nM of each primers except for reference primers (20 nM)), 2 µl Mix containing 25 
 7 
probes (100 nM of each probes) and water. The reaction was subjected to denaturation at 1 
95°C for 2 min followed by 40 cycles of denaturation at 95°C for 45 s, annealing/elongation 2 
at 60°C for 1 min. Samples were tested in triplicate and negative and positive controls were 3 
included with each run. The positive control was DNA purified from 027/NAP1/BI strain and 4 
the negative control was water. Fluorescent signal was measured at the end of the 5 
annealing/elongation step in each cycle. In case of indeterminate results (defined by one 6 
positive duplicate out of 3) or invalid result (defined by a negative signal with the internal 7 
control), fresh stools were retested including DNA extraction.  8 
Real-time PCR, cytotoxicity assay, culture and identification of the epidemic clone 9 
027/NAP1/BI by PCR-ribotyping were performed respectively by 4 different technicians who 10 
were blinded to the results of the other. 11 
 12 
Analytical performances 13 
Detection limit of the multiplex real-time PCR was estimated from ten-fold serial dilutions of 14 
purified genomic DNA from strains 027/NAP1/BI (BI 18). Analytical sensitivity of the real-15 
time PCR was assessed by spiking 1 g of pooled C. difficile culture negative-feces with ten-16 
fold dilution of different toxigenic strains including CD196, VPI 10463 and ATCC 43598. 17 
Sensitivity of the real-time PCR was compared to culture on TCCA (taurocholate, 18 
cycloserine, cefoxitin agar) medium. Specificity was evaluated from DNA extracted from 19 
different Clostridium spp. other than C. difficile including C. bifermentans, C. amygdalinum, 20 
C. innocuum, C. ramosum, C. sordellii, C. perfringens, C. tertium, and  C. sphenoides. 21 
 22 
Cell culture cytotoxicity neutralization assay 23 
The cytotoxicity assay was performed using MRC-5 cells. Fresh stool specimens were diluted 24 
in PBS (1:10 [wt/vol]) and centrifuged at 2,500 g for 30 min. The supernatant was passed 25 
 8 
through a 0.45 m-pore-size filter and inoculated onto confluent monolayers of MRC-5 cells 1 
in 96-well microtiter plates that were incubated at 37°C in a 6.5% CO2 atmosphere for 48 h. 2 
The final dilution of the fecal filtrate in each well was 1:100. Samples were considered 3 
positive if a characteristic cytopathic effect (cell rounding) was observed for at least 50% of 4 
the cells and could be neutralized with anti-Clostridium sordellii antiserum (obtained from M. 5 
R. Popoff, National Reference Center for Anaerobes, Institut Pasteur, Paris, France). The in 6 
vitro determination of the cytotoxicity of C. difficile isolates was performed by inoculating 7 
two to five colonies into trypticase yeast broth that was incubated 5 days under anaerobic 8 
conditions. The supernatant from this culture was filtered and inoculated on MRC-5 cells as 9 
described above. This method is referred as the toxigenic culture. 10 
 11 
Direct and enrichment culture 12 
Direct culture was performed on selective medium TCCA (brain heart infusion agar 13 
supplemented with 5% defibrinated horse blood, 0.1% taurocholate, 250 g/ml cycloserine, 14 
and 10 g/ml cefoxitin), and plates were incubated for 48 h in an anaerobic atmosphere. 15 
Presumptive identification was based on colony morphology, typical odor, and Gram staining. 16 
Identification was confirmed by use of an enzymatic profile from the RapID32A gallery 17 
(bioMérieux, La Balme les Grottes, France).  18 
Stools that were real-time PCR-positive and direct culture-negative were thawed and analyzed 19 
using an enrichment procedure. Briefly, stools were inoculated in pre-reduced taurocholate, 20 
cycloserine-cefoxitin brain heart infusion broth (TCC broth) and incubated for 48h at 37°C in 21 
an anaerobic atmosphere. Then, 100 l of the broth were subcultured in a second TCC broth, 22 
which was incubated for an additional 48 h in anaerobic atmosphere. Each TCC broth was 23 
plated on TCCA agar. Strains were stored at –80°C in one ml of brain heart infusion broth 24 
containing 10% glycerol. 25 
 9 
 1 
Identification of the NAP1/027/BI strain. 2 
The identification of the 027/NAP1/BI was based both on PCR ribotyping and tcdC 3 
sequencing. 4 
PCR-ribotyping. PCR ribotyping consists in a comparison of patterns of PCR products of the 5 
16S-23S rRNA intergenic spacer region, as previously described (9). Briefly PCR reactions 6 
were performed in a 100 µl final volume (50 mM KCl, 10mM Tris-HCl (pH 8.8), 1.5 mM 7 
MgCl2, 200  µM of each dNTP, 100 pmol of each primer, 2.5U of Taq polymerase and 10 µl 8 
of template DNA). PCR amplifications were performed for 35 cycles of 1 min at 94°C, 1 min 9 
at 57°C, 2 min at 72°C. PCR products were analyzed on a 3% Resophor agarose gel (BioRad, 10 
Ivry, France). An epidemic strain 027/NAP1/BI was used as a control in each run. 11 
TcdC sequencing. A 343-bp fragment of the tcdC gene from toxinotype III strains was 12 
sequenced on an AB3100 DNA sequencer (Applied Biosystems, Foster City, CA). Briefly, 13 
PCR was carried out using the primers tcdC-F: GGGAGATTGTATTATGTTTTCTAAA and 14 
tcdC-R: CTTTTTTAGCTTCTTCAGCTT. We purified amplified DNA by enzymatic 15 
procedures; 8 µl of PCR products were incubated with 2.5 U of exonuclease I (USB Corp., 16 
Cleveland, OH) and 0.25 U of shrimp alkaline phosphatase (USB Corp., Cleveland,  OH), 17 
with a final volume of 10 µl, at 37°C for 15 min before enzyme inactivation at 80°C for 15 18 
min. Then, we added 2 µl of BigDye v3.1, 4 µl of BigDye v3.1 buffer (Applied Biosystems, 19 
Foster City, CA), and 200 nM of primer for a final volume of 20 µl. The sequencing mixture 20 
was denatured at 96°C for 1 min, followed by 40 cycles of denaturation at 96°C for 30 s, 21 
annealing at 56°C for 15 s, and extension at 60°C for 4 min. Sequences were compiled and 22 
analyzed using Gap4 (http: //staden.sourceforge.net/manual/gap4_unix_2.html). 23 
 24 
Statistical methods 25 
 10 
Sample size : based on an expected sensitivity and specificity of 90%, alpha of 5% and an 1 
expected prevalence of the disease of 15%, we hypothesize that 927 stool specimens should 2 
be included to estimate sensitivity and specificity with 5% of accuracy. 3 
Descriptive analysis was performed with SAS V9 system (SAS Institute, Cary, NC, USA). 4 
Specificity, sensitivity, negative and positive predictive values and their 95% confidence 5 
intervals (CI) were calculated using R software version 2.0 (R foundation for statistical 6 
Computing, Vienna, Austria, www.R-project.org)  7 
8 
 11 
 1 
RESULTS 2 
 3 
Specificity and analytical sensitivity 4 
Sensitivity tests demonstrated that the real-time PCR assay efficiently detected tcdB from all 5 
the 67 toxigenic C. difficile strains tested. Moreover, deletion at position 117 of the tcdC gene 6 
was detected in all the 28 strains from PCR ribotype 027/NAP1/BI and in none of the 40 other 7 
strains. Interestingly, 4 strains of toxinotype III with a PCR-ribotyping pattern close but 8 
different from 027/NAP1/BI strains by at least one faint band, did not harbour the deletion at 9 
position 117, both by tcdC sequencing and real-time PCR.  10 
The threshold detection of the multiplex real-time PCR for tcdB and tcdC was 10 picograms 11 
of genomic DNA of 027/NAP1/BI strain.  12 
Analytical sensitivity of the multiplex real-time PCR, estimated from spiked fecal specimens 13 
with different concentration of the target bacteria, was 10 CFU per g of stools for tcdB, and 14 
100 CFU for tcdC.  15 
All the 8 Clostridium spp. other than C. difficile strains tested including C. sordellii, which 16 
carries a closely related lethal toxin gene, showed no amplification signal, thereby 17 
demonstrating the specificity of the PCR assay. 18 
 19 
Clinical performances 20 
The prevalence of positive cytotoxicity assay and toxigenic culture were 6.58% (58/881) and 21 
9.31% (82/881), respectively. The overall agreement between the real-time PCR and the 22 
cytotoxicity assay was 95.45%. Using the cytotoxicity assay as a gold standard, the 23 
sensitivity, specificity, positive and negative predictive values of real-time PCR were 94.83% 24 
 12 
(95% CI, 89.13 to 100%), 95.5% (95% CI, 94.06 to 96.94%), 60.44% (95% CI, 50.39 to 1 
70.49%) and 99.61% (95% CI, 99.18 to 100), respectively. 2 
Compared to the toxigenic culture, the sensitivity, specificity, positive and negative predictive 3 
values were 86.59%, 97.43%, 78.02% and 98.57% for the real-time PCR and 70.73%, 100%, 4 
100% and 97.08% for the cytotoxicity assay (table 2). 5 
The cycle threshold for the PCR positive-samples for tcdB ranged from 25 cycles to 39 6 
cycles, thereby showing a wide variation in the bacterial load of toxigenic C. difficile in feces 7 
of patients with CDI.  8 
Twenty stool specimens were toxigenic culture-negative and real-time PCR positive. Among 9 
them, 14 were thawed and processed to enriched culture in selective broth and 5 (35.7%) 10 
turned out to be positive for toxigenic C. difficile.  11 
Conversely, 11 stool specimens were toxigenic culture-positive and real-time PCR negative. 12 
DNA from the corresponding isolates was extracted and used for real-time PCR 13 
amplifications and all were positive for tcdB. 14 
Real-time PCR for detecting tcdB gave indeterminate and invalid results in 10 (1.14%) and 43 15 
(4.88%) cases, respectively. After repeated testing, these figures dropped to 1 (0.11%) and 20 16 
(2.27%), respectively. All these 21 unresolved results were actually negative with the 17 
cytotoxicity assay and the toxigenic culture. Two stool specimens (0.2%) exhibited 18 
indeterminate result by the cytotoxicity assay due to a non specific cytotoxic effect leading to 19 
a disruption of the cell layer.  20 
The epidemic clone 027/NAP1/BI was neither detected by real-time PCR nor by the gold 21 
standard assay.  However, the five frozen stool specimens from patients infected with the 22 
epidemic 027 strains gave a positive result for both tcdB and tcdC.  23 
24 
 13 
 1 
DISCUSSION 2 
 3 
C. difficile infection has become a major nosocomial pathogen in many healthcare facilities  4 
including hospitals, long term facilities and nursing homes. Therefore a rapid and accurate 5 
diagnosis is crucial for appropriate antibiotic therapy and for the timely implementation of 6 
infection control measures, more specially in the context of outbreaks of the hypervirulent 7 
027/NAP1/BI strain. 8 
The toxigenic culture is considered as the most sensitive method for the diagnosis of CDI but 9 
this method is slow and laborious, often requires 48-72 hours to complete and therefore is 10 
unlikely to be adopted by clinical laboratory as the standard method for C. difficile testing. 11 
Stool cytotoxicity assay, which has been also considered as a gold standard for a long time, is 12 
not standardized, needs cell culture facilities, and results are not obtained before 24-48 hours. 13 
Nowadays, many laboratories routinely use enzyme immunoassay (EIA) for toxin detection. 14 
However clinical trials recently demonstrated that EIAs for toxins A and B are not sensitive 15 
enough to be used as a stand-alone technique for the diagnosis of CDI (15, 17, 32, 37, 38). 16 
Moreover, their poor sensitivity often encourages physicians to order additional testing 17 
following the first EIA-negative result, if suspicion of CDI remains high (10). However, the 18 
gain of repeat testing has been shown to be low (1, 10). 19 
To enhance rapidity and sensitivity of CDI diagnosis, experts now recommend to implement a  20 
two or three-step algorithm using glutamate dehydrogenase (GDH) detection as a screening 21 
method (14, 15). This strategy is based on the high negative predictive value of the GDH 22 
detection (33, 40, 43). However this antigen is also found in non-toxigenic C. difficile strains 23 
and therefore any positive result must be confirmed by a more specific assay detecting toxins. 24 
As of today, the choice of confirmation assay is still matter of debates. Some recent clinical 25 
 14 
trials reported lower sensitivities (between 70% and 88%) for GDH assays (17, 26). Tenover 1 
et al. have recently showed that the sensitivity of GDH for the detection of non-027 strains 2 
was significantly lower than real-time PCR, suggesting that the variable sensitivities of GDH 3 
assays might be explained by the hospital-to-hospital variations of C. difficile strains (37). 4 
Another study has shown that freezing-thawing of stool sample may also affect GDH 5 
detection (34). 6 
Another recent option for the diagnosis of CDI is to use real-time PCR. Thus, we developed a 7 
real-time PCR assay for the rapid detection of all toxigenic strains from fecal samples and the 8 
presumptive identification of the epidemic 027 clone, based on the direct detection of tcdB 9 
gene sequence and the single base deletion at nucleotide 117 of the tcdC gene. The analytical 10 
sensitivity of this assay was excellent with a detection threshold calculated from spiked fecal 11 
samples of 10 UFC/g of stools for tcdB and 100 UFC/g stools for tcdC. This detection limit is 12 
much lower that those previously reported by Belanger et al. (5.10
4
 CFU/g of stools) or van 13 
den Berg (10
5
 CFU/g of stools) (8, 41).   14 
To date, four different amplification assays have been recently cleared by the FDA for 15 
laboratory use in the US. These assays target tcdB (ProGastro Cd, Prodesse; BD GeneOhm C. 16 
diff, BD Diagnostics), tcdA (Illumigene Meridian) or tcdB in combination with binary toxin 17 
and deletion of tcdC (Xpert C. difficile, Cepheid). These assays have been compared to 18 
toxigenic culture in several clinical trials. A review of clinical performances indicated that 19 
their sensitivity and specificity range from 77.3% to 97.1% and 93% to 100%, respectively 20 
(table 3) (4, 17, 22, 25, 31, 35-38). The performance characteristics of our in-house real-time 21 
PCR assay are in agreement with those data, with a sensitivity and a specificity of 86.6 and 22 
97.4%, respectively. It performs better than the cytotoxicity assay when using the toxigenic 23 
culture as the gold standard method. 24 
 15 
Among the 20 specimens that were PCR-positive but toxigenic culture-negative, 14 were 1 
cultured using an enrichment method. Interestingly, among these, 5 (35.7%) appeared to be 2 
true positive by enriched toxigenic culture. The corrected sensitivity and specificity of the 3 
real-time PCR would be 87.3% and 98.05%, respectively. The reasons why direct toxigenic 4 
culture appeared negative could include a low concentration of microorganisms in very 5 
heterogeneous sample or a growth inhibition due to previous therapy for C. difficile.  6 
 7 
The hands-on technologist time of our real-time PCR is about approximately 30 min., which 8 
is similar to other types of detection assays used for C. difficile  (cytotoxicity assay, EIA). To 9 
date, the only test that showed a significant shorter hands-on-time is the Gene Xpert C. diff 10 
(Cepheid) where DNA extraction and PCR reaction are fully automated and performed in the 11 
same cartridge (22, 37).  Another main advantage of real-time PCR is the rapid turn-around 12 
time. Specimen processing, miniMag extraction and testing by the real-time PCR took 13 
approximately 3 hours before the results were reported. This time is considerably shorter than 14 
the 24-48h for the cytotoxicity assay and much shorter than the 3-5 days for the toxigenic 15 
culture.  16 
 17 
The real-time PCR assay we developed may rise several questions. 18 
First, there is a practical concern regarding the clinical specificity of this assay. Actually, real-19 
time PCR is able to detect toxin genes but not the toxin itself. Because asymptomatic carriage 20 
of toxigenic strains is proportional to the length of stay and may reach 50% after 4 weeks of 21 
hospitalization (12), the clinical significance of toxigenic strain remains uncertain. However, 22 
whereas it is true that the isolation of a toxigenic strain of C. difficile does not prove that the 23 
patient is infected, it is also true that it is the most likely cause of the diarrhea (16, 21). The 24 
risk of real-time PCR as well as toxigenic culture is to treat by excess patients who are simply 25 
 16 
colonized by a toxin producing strain. Microbiologists should be aware of this limitation 1 
when interpreting the result.  2 
The second limitation is the potential genetic change in tcdB gene or the emergence of tcdA
+ 
3 
tcdB
-
 strains, resulting in false negative results. To date, these trends are still hypothetical and 4 
the emergence of new genotypes affecting clinical performances of real-time PCR for tcdB 5 
remains undocumented. Nevertheless, it will be important to periodically monitor the 6 
emergence of new genotypes, which could negatively impact performances of tcdB-based 7 
assays. During the development of our real-time PCR, we have tested our primers and probes 8 
on 68 strains including the most common toxinotypes and all were positive. Moreover, strains 9 
isolated from toxigenic culture-positive and real-time PCR-negative stools, tested positive 10 
when DNA from these strains was used as template for PCR, suggesting that false negative 11 
results were not associated with a mismatch of primers and/or probes.  12 
The third limitation of our real time PCR assay is the high rate (6.01%) of unresolved results 13 
upon initial testing, mainly due to a negative result for the internal control. That might be 14 
explained either by an inhibition of PCR reaction or by DNA extraction failure. The rate 15 
dropped to 2.38% after repeated testing. A review of the recent literature indicated that the 16 
rate of unresolved results with other commercially available real-time PCR are similar and 17 
range from 0% to 3.3%. However, it should be emphasized that some PCR-based methods 18 
commercially available do not have an internal control for DNA extraction (BD GeneOhm C. 19 
diff), and therefore cannot delineate true negative result from DNA extraction failure.  20 
 21 
During the clinical trial, the epidemic 027/NAP1/BI strain was not detected. This result is in 22 
agreement with a recent national survey of C. difficile infection where 027 represented only 23 
3.6% (8/224) of all isolates (Eckert C. et al., 50
th
 ICAAC, Boston, 12-15 September 2010). As 24 
a consequence, the sensitivity of our real-time PCR for the identification of the 027/NAP1/BI 25 
 17 
strain could not be calculated. Nevertheless no false positive result in tcdC was observed, 1 
suggesting that the specificity of the real-time PCR for tcdC deletion was 100%. It also 2 
suggests that the deletion at nt 117 is not found in other strains of C. difficile and remains 3 
specific of the epidemic 027/NAP1/BI strain. To overcome the lack of 027/NAP1/BI strains 4 
in our population, the real-time PCR was performed from 5 frozen stools of patients infected 5 
by the 027/NAP1/BI and all were positive both for tcdB and tcdC. Among the commercial 6 
multiplex real-time PCR assays, only the Xpert C. difficile (Cepheid) is able to detect the 7 
presumptive PCR-ribotype 027 strain with a sensitivity and specificity of 100 and 98.1%, 8 
respectively (22).  9 
 10 
 11 
In summary, our data suggest that sensitivity and specificity of our real-time PCR are 12 
comparable to those of commercially available real-time PCR. The rapid turn-around time of 13 
real-time PCR would allow laboratories to speed up the detection of toxigenic strains and 14 
consequently to improve management of patients with CDI. However, the savings realized 15 
with a rapid and accurate diagnostic method should be further evaluated.   16 
 17 
 18 
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TABLE 1: Primers and probes used in the PCR assays. 1 
 2 
Target Efficiency*
 
 Length Primer and 
probe 
Sequences  
Rv3865 1,74 – 1,90 
 
65 bp Forward CGAGTTCAGCTTACCCATGGTT 
Reverse CAAACTCTTGCAGCGTGTCATT 
Probe TTCACGTCGAAATT-NED* 
tcdB 1,63 – 1,88 
 
197 bp Forward ATGCAGCCAAAGTTGTTGAA 
Reverse CTGCCATTATACCTATCTTAGCTTC 
Probe AGTGACCCATTATT-VIC* 
tcdC 1,65 – 1,91 
 
145 bp Forward GAAATGACCTCCTCATGGTCT 
Reverse AGTAATGAAAGAAAAGGAAGCTCT
AA 
Probe ACACACCAAAATA-FAM* 
*
Triplex oligos efficiency depends on  the number (3 – 1) of targets amplified. pour coller avec le sens 3 
des efficacités, ex Rv3865 : 1,74 pour triplex (3) et 1,90 pour simplex (1)  4 
 5 
 6 
 23 
 
TABLE 2 : Performances of cytotoxicity assay and real-time PCR for the detection of toxigenic strains of C. difficile. 
__________________________________________________________________________________________________ 
Assay         Toxigenic culture       Assay performance (95% confidence interval) 
   ________________________ Sensitivity  Specificity  PPV   NPV 
          (%)        (%)   (%)   (%) 
   Negative  Positive 
__________________________________________________________________________________________________ 
Cytotoxicity assay 
Negative  797 24   70.7   100   100  97.08  
Positive  0 58      (60.88-80.58)      (95.91-98.25)     (96.19-98.35) 
Total   797 82 
Real-Time PCR 
 Negative  758 11   86.59  97.43   78.02  98.57  
Positive  20 71  (79.21-93.97)       (96.32-98.54)       (69.51-86.53)   (97.74-99.4)  
Total   778 82 
__________________________________________________________________________________________________ 
 
 
 
 
 24 
TABLE 3 : Comparison of commercially real-time PCR performances for the detection of toxigenic strains of C. difficile.  
Authors (year) Assay Target No 
samples 
Sensitivity 
(%) 
Specificity 
(%) 
Gold standard Indet. 
(%) 
Preval. 
(%) 
Barbut F. (2009) 
BD GeneOhm 
C. diff assay 
tcdB 
300 93.9 97.7 TC 3.3 11 
Stamper P. (2009) 404 83.6 98.2 TC 0.5 15.2 
Kvach E. (2010) 400 91.4 100 TC 0 26.2 
Terhes G. (2009) 600 96.4 99.1 CTA 
(+TC for 
discrepant results) 
0  9.2 
Eastwood K. (2010) 558 88,5 95.4 
TC 
1 .1 18.6 
Huang H. (2009) 
 
Cepheid 
Xpert C. diff. 
tcdB 
tcdC 
binary toxin 
gene 
220 97.1 93 CTA 
(+ TC for 
discrepant results) 
0 9.2 
Tenover F. (2010) 2296 
(multicenter) 
93.5 94 
Enriched TC 
0.4 14.7 
Novak-Weekley S. (2010) 432 94.4 96.3 TC 0.9 19.6 
Stamper P. (2009) 
ProGastro Cd assay 
(Prodesse) 
tcdB 285 77.3 99.2 TC 1.4 15.7 
This study  
tcdB 
tcdC 
 
881 86.6 97.4 TC 2.4 9.3 
 25 
TC: toxigenic culture ; CTA: stool cytotoxicity assay ; Indet.: indeterminate results; Preval.: prevalence 
 
